Medical Sciences Campus Clinical Research Development P*

$1,414,137P20FY2005RRNIH

University Of Puerto Rico Med Sciences, San Juan PR

Investigators

Linked publications & trials

Paper 28746408 Paper 27135036 Paper 26220577 Paper 26167513 Paper 25244879 Paper 24397214 Paper 24241256 Paper 23983008 Paper 23422638 Paper 23411421 Paper 23291538 Paper 23063415 Paper 22774315 Paper 22643485 Paper 22629383 Paper 22364955 Paper 22343096 Paper 21801849 Paper 21784411 Paper 21698649 Paper 21616477 Paper 21449494 Paper 21275602 Paper 21257128 Paper 21137088 Paper 21125319 Paper 21070450 Paper 20935057 Paper 20932851 Paper 20921898 Paper 20799519 Paper 20799508 Paper 20696771 Paper 20691403 Paper 20664723 Paper 20657745 Paper 20627945 Paper 20579848 Paper 20521413 Paper 20521412 Paper 20521409 Paper 20521398 Paper 20498010 Paper 20496524 Paper 20473659 Paper 20391486 Paper 20331884 Paper 20300024 Paper 20223601 Paper 20222330 Paper 20222329 Paper 20222328 Paper 20156074 Paper 20128912 Paper 20123819 Paper 20118158 Paper 20096398 Paper 20012372 Paper 20001856 Paper 19954080 Paper 19901616 Paper 19892816 Paper 19850658 Paper 19762396 Paper 19715116 Paper 19714612 Paper 19610574 Paper 19578107 Paper 19531324 Paper 19530550 Paper 19513023 Paper 19479701 Paper 19454606 Paper 19438980 Paper 19398292 Paper 19374515 Paper 19342095 Paper 19242102 Paper 19238159 Paper 19233884 Paper 19188847 Paper 19157247 Paper 19151125 Paper 19115125 Paper 19101040 Paper 19069365 Paper 19069357 Paper 19004040 Paper 18951626 Paper 18759263 Paper 18646350 Paper 18646342 Paper 18646341 Paper 18646340 Paper 18616042 Paper 18565248 Paper 18511474 Paper 18484174 Paper 18450230 Paper 18413418

Abstract

[unreadable] Description (from information provided by applicant): To compare the steady state area under the concentration-time-curve between 0 and 12 hours (AUCo-12) of ZDV-MP, ZDV-TP, and dTTP in PBMCs from HIV-HCV co-infected patients before and after REBETRON(r) OR PEG-lNTRON(tm) plus Ribavirin therapy. To compare the systemic exposure (AUCo-12) of nelfinavir before and after Rebetron OR PEGINTRON (tm) plus Ribavirin therapy in HIV-HCV co-infected patients. [unreadable] [unreadable] To describe the effect of REBETRON(r) OR PEG-lNTRON(tm) plus Ribavirin in HCV-RNA viral titers, [unreadable] alanine aminotransferase (ALT) levels, CD4+, and HIV-RNA viral titers in HIV-HCV co-infected [unreadable] patients during the 48 weeks of treatment. Also, to describe the effect of REBETRON(r) OR PEGINTRON [unreadable] (tm) plus Ribavirin in liver histology at week 72. [unreadable] [unreadable]

View original record on NIH RePORTER →